From: Immunotherapy in hematologic malignancies: past, present, and future
Study | Institution | No. of patients | Disease (all relapsed/refractory) | Outcomes | Duration of CARs | Best duration of response | Comments |
---|---|---|---|---|---|---|---|
Jensen et al. (2010) [74] | City of Hope | 4 | NHL | No responses (2 with CR after autoHCT) | 1 week | – | 1st generation CAR |
NCI | 8 | NHL (4) and CLL (4) | 80% ORR (1 CR, 5 PR) | Up to 6Â months | >18Â months | 5/8 CRS 4/8 B cell aplasia | |
Savoldo et al. (2011) [77] | Baylor | 6 | NHL | 2 SD | 2nd generation—up to 6 months | – | Infusion of 1st and 2nd generation T cells in the same patient |
Brentjens et al. (2011) [78] | MSKCC | 10 | CLL (8) and ALL (2) | CLL—1 PR, 2 SD ALL—1 durable B cell aplasia | Up to 6 weeks (correlated with burden of disease) | 8 months | Most with CRS |
UPenn | 3 | CLL | 2 CR, 1PR | Up to 6Â months | >11Â months | All with CRS | |
MSKCC | 16 | ALL | 88% CR (78% in refractory disease) | Up to 4 months | 3 months (but 7 went on to alloHCT) | 7 CRS CRP, IFNγ, IL6 correlated with CRS | |
Kochenderfer et al. (2013) [82] | NCI | 10 | CLL (4) and NHL (6) post alloHCT | 1 PR, 1 CR, 6 SD | Up to 30Â days (used donor T cells) | 9Â months | No GVHD |
Kochenderfer et al. (2014) [83] | NCI | 15 | NHL (DLBCL and indolent lymphomas) | 8 CR, 4 PR, 1 SD | Up to 11Â weeks | 22Â months | 6/7 DLBCL with response |
Lee et al. (2014) [49] | NCI | 21 | ALL (20), NHL (1), 8 post alloHCT | 14 CR (13 MRD negative), correlated with CAR expansion | Up to 8Â weeks (most went on to alloHCT) | 19Â months | 3 severe CRS CRP, IL6, and CAR expansion correlated with CRS |
UPenn | 30 | ALL, 18 post alloHCT | 90% CR (15 post alloHCT, 2 post blinatumomab) | Up to 2Â years | 24Â months | All with CRS | |
Porter et al. (2015) [53] | UPenn | 14 | CLL | 57% ORR (4 CR and 4 PR) | >4Â years (no relapses) | >4Â years | All with CRS |
Brudno et al. (2016) [50] | NCI | 20 | B cell malignancies post alloHCT | 6 CR, 2 PR (4/5 ALL patients achieved MRD negativity) | – | >30 months (CR) | No new-onset GVHD; Higher peak blood CAR T cell levels correlated with response |
Turtle et al. (2016) [85] | FHCRC | 29 | ALL (12 post alloHCT) | 93% CR (27/29), 25 with MRD negativity | – | – | 25 CRS (3 deaths); No GVHD in post-alloHCT patients; CAR T cell grafts with defined CD4:CD8 ratio |